Exhibit 99.1
|
 AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 |
| Contact: | Barbara Brungess 610-727-7199 bbrungess@amerisourcebergen.com |
AMERISOURCEBERGEN ELECTS
STEVEN H. COLLIS TO BOARD OF DIRECTORS
STEVEN H. COLLIS TO BOARD OF DIRECTORS
VALLEY FORGE, PA, May 12, 2011 — AmerisourceBergen Corporation (NYSE: ABC) today announced that
Steven H. Collis, 49, President and Chief Operating Officer, was appointed to the Company’s Board
of Directors, effective immediately. Collis will serve as a member of the Executive and Finance
Committee of the Board. The Company previously announced that Collis will succeed R. David Yost,
63, as Chief Executive Officer when Yost retires from AmerisourceBergen on July 1, 2011.
Collis, a 17 year veteran of the Company, is currently responsible for all AmerisourceBergen
business units including AmerisourceBergen Drug Corporation (ABDC), AmerisourceBergen Specialty
Group (ABSG), AmerisourceBergen Consulting Services (ABCS), and AmerisourceBergen Packaging Group
(ABPG). Before being promoted to his current position in November 2010, Collis was Executive Vice
President AmerisourceBergen and President of ABDC, the Company’s largest subsidiary with revenues
over $60 billion. Over his tenure with the Company, he founded ABSG and was the driving force
behind growing the business into the market-leader it is today, with $16 billion in annualized
revenues.
The AmerisourceBergen Board of Directors is currently comprised of ten members. Mr. Yost will
retire from the Board when he retires from the Company on July 1, 2011.
About AmerisourceBergen
AmerisourceBergen is one of the world’s largest pharmaceutical services companies serving the
United States, Canada and selected global markets. Servicing both healthcare providers and
pharmaceutical manufacturers in the pharmaceutical supply channel, the Company provides drug
distribution and related services designed to reduce costs and improve patient outcomes.
AmerisourceBergen’s service solutions range from pharmacy automation and pharmaceutical packaging
to reimbursement and pharmaceutical consulting services. With $79 billion in annualized revenue,
AmerisourceBergen is headquartered in Valley Forge, PA, and employs approximately 10,000 people.
AmerisourceBergen is ranked #24 on the Fortune 500 list. For more information, go to
www.amerisourcebergen.com.
Forward-Looking Statements
Certain of the statements contained in this press release are “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These statements are based on management’s current expectations and are subject to
uncertainty and change in circumstances. Among the factors that could cause actual results to
differ materially from those projected, anticipated or implied are the following: changes in
pharmaceutical market growth rates; the loss of one or more key customer or supplier relationships;
changes in customer mix; customer delinquencies, defaults or insolvencies; supplier defaults or
insolvencies; changes in pharmaceutical manufacturers’ pricing and distribution policies or
practices; adverse resolution of any contract or other dispute with customers or suppliers; federal
and state government enforcement initiatives to detect and prevent suspicious orders of controlled
substances and the diversion of controlled substances; qui tam litigation for alleged violations of
fraud and abuse laws and regulations and/or any other laws and regulations governing the marketing,
sale and purchase of pharmaceutical products or any related litigation, including shareholder
derivative lawsuits; changes in federal and state legislation or regulatory action affecting
pharmaceutical product pricing or reimbursement policies, including under Medicaid and Medicare;
changes in regulatory or clinical medical guidelines and/or labeling for the pharmaceutical
products we distribute, including certain anemia products; price inflation in branded
pharmaceuticals and price deflation in generics; greater or less than anticipated benefit from
launches of the generic versions of previously patented pharmaceutical products; significant
breakdown or interruption of our information technology systems; our inability to continue to
implement an enterprise resource planning (ERP) system to handle business and financial processes
and transactions (including processes and transactions relating to our customers and suppliers) of
AmerisourceBergen Drug Corporation operations and our corporate functions as intended without
functional problems, unanticipated delays and/or cost overruns; success of integration,
restructuring or systems initiatives; interest rate and foreign currency exchange rate
fluctuations; economic, business, competitive and/or regulatory developments in Canada, the United
Kingdom and elsewhere outside of the United States, including changes and/or potential changes in
Canadian provincial legislation affecting pharmaceutical product pricing or service fees or
regulatory action by provincial authorities in Canada to lower pharmaceutical product pricing and
service fees; the impact of divestitures or the acquisition of businesses that do not perform as we
expect or that are difficult for us to integrate or control; our inability to successfully complete
any other transaction that we may wish to pursue from time to time; changes in tax legislation or
adverse resolution of challenges to our tax positions; increased costs of maintaining, or
reductions in our ability to maintain, adequate liquidity and financing sources; volatility and
deterioration of the capital and credit markets; and other economic, business, competitive, legal,
tax, regulatory and/or operational factors affecting our business generally. Certain additional
factors that management believes could cause actual outcomes and results to differ materially from
those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors) in the
Company’s Annual Report on Form 10-K for the Fiscal Year Ended September 30, 2010 and elsewhere in
that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act
of 1934.
###